Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871167/0/en/Soleno-Therapeutics-Receives-Breakthrough-Therapy-Designation-from-U-S-FDA-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome-PWS.html

First Ever Breakthrough Designation for a Drug Being Developed for PWS

Designation is Based on Data from the Phase 3 Program for DCCR

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.